

Electrophilic-Induced Cyclization Reaction of Hexahydroindolinone Derivatives and Its Application toward the Synthesis of (\pm) -Erysotramidine

Albert Padwa,* Hyoung Ik Lee, Paitoon Rashatasakhon, and Mickea Rose

Department of Chemistry, Emory University, Atlanta, Georgia 30322

chemap@emory.edu

Received August 4, 2004

A convenient synthesis of variously substituted octahydroindolo[7a,1a]-isoquinolinones has been achieved by an acid-induced cyclization of hexahydroindolinones bearing tethered phenethyl groups. The formation of a single lactam diastereomer is the result of the stereoelectronic preference for axial attack by the aromatic ring onto the initially formed N-acyliminium ion from the least hindered side. Additional experiments showed that a variety of hexahydroindolinones containing tethered π -bonds undergo a related acid-induced cyclization reaction. Treatment of the 3-methylbut-3-enylsubstituted hexahydroindolinone with acid furnished a 3:1 mixture of isomeric octahydropyrido-[2,1-i]indolinones in near-quantitative yield. Interestingly, cyclization of the closely related 1-(3methoxybut-3-enyl)-substituted hexahydroindolin-one afforded a pyrrolo[3,2,1-ij]quinolinone as the exclusive product. With this system, initial protonation takes place on the more nucleophilic enol ether π -bond and the resulting carbonium ion undergoes a subsequent cyclization with the enamido π -bond to give the observed product. The electrophilic promoted cyclizations were extended to include the related hexahydro[1]pyrindinone and 1H-quinolinone systems. An NBS-promoted intramolecular electrophilic aromatic substitution reaction of 1-[2-(3,4-dimethoxyphenyl)ethyl]-1,4,5,6-tetrahydroindolinone was used to assemble the tetracyclic core of the erythrinone skeleton. The resulting cyclized product was transformed into (\pm) -erysotramidine in three additional steps.

The hexahydroindolinone nucleus is a structurally characteristic component found in a wide variety of alkaloids,¹ including the amaryllidaceae,² aspidosperma,³ erythrina,⁴ and strychnos⁵ families. The distinctive structural feature of these natural products sharing the hexahydroindolinone framework has attracted much attention in synthetic organic chemistry.⁶ Strategies to prepare this skeleton include [4 + 2]-cycloadditions,⁷ sigmatropic rearrangements,8 Pummerer-induced cy-

10.1021/io048647f CCC: \$27.50 © 2004 American Chemical Society Published on Web 10/28/2004

clizations,9 intramolecular condensation of amines onto carbonyl compounds,¹⁰ 1,3-dipolar cycloadditions,¹¹ reactions of isocyanates with isocyanides,12 and transitionmetal-mediated cyclization reactions.¹³ The related 1-azaspirocyclic structure of the erythrina alkaloids has long been of interest in development of synthetic strate-

^{(1) (}a) Martin, S. F. In *The Alkaloids*; Brossi, A., Ed.; Academic Press, Inc.: New York, 1987; Vol. 30, pp 251–377. (b) Lewis, J. R. *Nat. Prod. Rep.* **1994**, *11*, 329. Jeffs, P. W. In *The Alkaloids*; Rodrigo, R. G. A., Ed.; Academic Press: New York, 1981; Vol. 19, pp 1-80.

^{(2) (}a) Cordell, G. A. In The Alkaloids; Manske, R. H. F., Rodrigo, R. G. A., Eds.; Academic Press: New York, 1979; Vol. 17, pp 199– 384. (b) Saxton, J. E. Nat. Prod. Rep. **1993**, 10, 349–395.

^{(3) (}a) Boekelheide, V. Alkaloids **1960**, 7, 201. (b) Hill, R. K. In *The Alkaloids*; Manske, R. H. F., Ed.; Academic Press: New York, 1967; Vol. 9, p 483.

⁽⁴⁾ Dyke, S. F.; Quessy, S. N. In The Alkaloids; Rodrigo, R. G. A., (5) (a) Massiot, G.; Delaude, C. In *The Alkaloids*; Brossi, A., Ed.;

Academic Press: San Diego, CA, 1988; Vol. 34, pp 211-329. (b) Aimi, N.; Sakai, S.; Ban, Y. In *The Alkaloids*; Brossi, A., Ed.; Academic Press: San Diego, CA, 1989; Vol. 36, pp 1–68. (c) Bosch, J.; Bonjoch, J.; Amat, M. In *The Alkaloids*; Brossi, A., Ed.; Academic Press: San

⁽⁶⁾ For some leading references, see: (a) Banwell, M. G.; Wu, A. W. *J. Chem. Soc., Perkin Trans.* 1 1994, 2671. (b) Grothjahn, D. B.;
Vollhardt, K. P. C. Synthesis 1993, 579. (c) Pearson, W. H.; Schkeryantz, J. M. J. Org. Chem. **1992**, 57, 6783. (d) Backvall, J. E.; Andersson, P. G.; Stone, G. B.; Gogoll, A. J. Org. Chem. **1991**, 56, 2988. (e) Jolly, R. S.; Livinghouse, T. J. Am. Chem. Soc. **1988**, 110, 7536. (f) Stork, G.; Mah, R. Heterocycles **1989**, 28, 723.

^{(7) (}a) Kuehne, M. E.; Matsko, T. H.; Bohnert, J. C.; Motyka, L.; Oliver-Smith, D. J. Org. Chem. **1981**, 46, 2002. (b) Kuehne, M. E.; Earley, W. G. Tetrahedron **1983**, 39, 3707. (c) Kuehne, M. E.; Brook, C. S.; Xu, F.; Parsons, R. Pure Appl. Chem. 1994, 66, 2095. (d) Nkiliza, J.; Vercauteren, J. Tetrahedron Lett. 1991, 32, 1787. (e) Rawal, V. H.; Michoud, C.; Monestel, R. F. J. Am. Chem. Soc. 1993, 46, 3030.

^{(8) (}a) Overman, L. E.; Sugai, S. Helv. Chim. Acta 1985, 68, 745. (b) Overman, L. E.; Robertson, G.; Robichaud, A. J. J. Org. Chem. 1989, 54, 1236. (c) Overman, L. E.; Sworin, M.; Burk, R. M. J. Org. Chem. 1983, 48, 2685.

^{(9) (}a) Magnus, P.; Gallagher, T.; Brown, P.; Pappalardo, P. Acc. Chem. Res. 1984, 17, 35. (b) Gallagher, T.; Magnus, P.; Huffman, J. C. J. Am. Chem. Soc. 1983, 105, 4750. (c) Desmaële, D.; d'Angelo, J. Org. Chem. 1994, 59, 2292.
 (10) (a) Kraus, G. A.; Thomas, P. J.; Bougie, D.; Chen, L. J. Org.

Chem. 1990, 55, 1624. (b) Sole, D.; Bonjoch, J. Tetrahedron Lett. 1991, 32, 5183. (c) Bonjoch, J.; Sole, D.; Bosch, J.; J. Am. Chem. Soc. 1993, 115, 2064. (d) Schultz, A. G.; Guzzo, P. R.; Nowak, D. M. J. Org. Chem. 115, 2064. (d) Schultz, A. G.; Guzzo, P. R.; Nowak, D. M. J. Org. Chem.
1995, 60, 8044. (e) Schultz, A. G.; Holoboski, M. A.; Smyth, M. S. J. Am. Chem. Soc. 1993, 115, 7904. (f) Schultz, A. G.; Holoboski, M. A.; Smyth, M. S. J. Am. Chem. Soc. 1996, 118, 6210.
(11) (a) Padwa, A.; Price, A. T. J. Org. Chem. 1995, 60, 6258. (b) Pearson, W. H.; Postich, M. J. J. Org. Chem. 1994, 59, 5662.
(12) (a) Rigby, J. H.; Qabar, M.; Ahmed, G.; Hughes, R. C. Tetrahedron 1993, 49, 10219. (b) Rigby, J. H.; Laurent, S.; Cavezza, A.; Heeg, M. J. Low. Chem. 1009, 63, 5587. (c) Rigby, J. H.; Hughes, R. C.

M. J. J. Org. Chem. **1998**, 63, 5587. (c) Rigby, J. H.; Hughes, R. C.; Heeg, M. J. J. Am. Chem. Soc. **1995**, 117, 7834. (d) Rigby, J. H.; Mateo, M. E. Tetrahedron **1996**, 52, 10569. (e) Rigby, J. H.; Qabar, M. H. J. Org. Chem. 1993, 58, 4473.



FIGURE 1.

gies for the efficient formation of their core ring system.¹⁴ Erythrina alkaloids are generally classified into two groups according to their structural features:¹⁵ those whose D-rings are aromatic (e.g., 3-demethoxyerythratidinone (1) and erysotramidine (2)) and the others whose D-rings possess an unsaturated lactone (e.g., cocculolidine (3) (Figure 1).¹⁶ Many different approaches have been employed for the synthesis of this class of natural products. Taking the final step of bond formation into consideration, the methods for building up the erythrinan ring system can be loosely classified into seven different reaction types: (1) C-ring formation with the C-5 quaternary center being constructed by intramolecular cyclization;¹⁷ (2) C-ring formation by electrophilic substitution;¹⁸ (3) A-ring formation by an intramolecular aldol reaction;¹⁹ (4) A-ring formation from a benzoindolizidine fragment;²⁰ (5) B-ring formation utilizing a C-5 spiroisoquinoline system;²¹ (6) B- and C-ring formation by intramolecular annulation of dibenzazonine:²² and (7) an assortment of miscellaneous methods.²³

On the basis of our earlier work with the erythrina skeleton,²⁴ we felt that a suitably substituted hexahydroindolinone N-acyliminium ion precursor might allow for a facile entry to the tetracyclic core of erysotramidine (2). N-Acyliminium ions have historically occupied an important position as versatile intermediates for the

(15) Tsuda, Y.; Sano, T. In The Alkaloids; Cordell, G. A., Ed.; (16) Forest: San Diego, 1996; Vol. 48, pp 249–337.
 (16) Kawasaki, T.; Onoda, N.; Watanabe, H.; Kitahara, T. Tetrahe-

dron Lett. 2001, 42, 8003.

(17) (a) Belleau, B. J. Am. Chem. Soc. 1953, 75, 5765. (b) Mondon, A.; Hansen, K. F. Tetrahedron Lett. 1960, 5. (c) Ishibashi, H.; Sato, T.; (d) Tsuda, Y.; Hosoi, S.; Ishida, K.; Sangai, M. Chem. Pharm. Bull. (u) Isuua, 1., 110501, S.; ISHIQA, K.; Sangal, M. Chem. Pharm. Bull.
1994, 42, 204. (e) Cassayre, J.; Quiclet-Sire, B.; Saunier, J.-B.; Zard, S. Z. Tetrahedron Lett. 1998, 39, 8995. (f) Rigby, J. H.; Deur, C.; Heeg, M. J. Tetrahedron Lett. 1999, 40, 6887. (g) Parsons, A. F.; Williams, D. A. Tetrahedron 2000, 56, 7217. (h) Toyao, A.; Chikaoka, S.; Takeda, V.; Tawura, Q.; Murgaka, Q.; Takaba, C.; Lebilachi, H. T. K.; Kanga, Kanga, Kanga, Kanga, Kanga, K D. A. Tetrahedron 2000, 50, 7217. (II) 10940, A., Chikaota, S., Takedron, Y.; Tamura, O.; Muraoka, O.; Tanabe, G.; Ishibashi, H. Tetrahedron Lett. 2001, 42, 1729. (i) Miranda, L. D.; Zard, S. Z. Org. Lett. 2002, 4, 1135. (j) Allin, S. M.; James, S. L.; Elsegood, M. R. J.; Martin, W. P. J. Org. Chem. 2002, 67, 9464. (k) Guerrero, M. A.; Cruz-Almanza, R.; Miranda, L. D. Tetrahedron 2003, 59, 4953.

(18) (a) Toda, J.; Niimura, Y.; Takeda, K.; Sano, T.; Tsuda, Y. Chem. Pharm. Bull. 1998, 46, 906. (b) Jousse, C.; Demaële, D.; Eur. J. Org. Chem. 1999. 909.

(19) Wasserman, H. H.; Amici, R. M. J. Org. Chem. 1989, 54, 5843. (20) (a) Sano, T.; Toda, J.; Kashiwaba, N.; Ohshima, T.; Tsuda, Y. Chem. Pharm. Bull. 1987, 35, 479. (b) Tsuda, Y.; Hosoi, S.; Katagiri, N.; Kaneko, C.; Sano, T. Heterocycles 1992, 33, 497

(21) (a) Danishefsky, S. J.; Panek, J. S. J. Am. Chem.. Soc. 1987, 109, 917. (b) Ahmed-Schofield, R.; Mariano, P. S. J. Org. Chem. **1987**, 52, 1478. (c) Irie, H.; Shibata, K.; Matsuno, K.; Zhang, Y. *Heterocycles* **1989**, 29, 1033. (d) Kawasaki, T.; Onoda, N.; Watanabe, H.; Kitahara, T. Tetrahedron Lett. 2001, 42, 8003.

construction of a wide array of nitrogen-containing molecules, due to their susceptibility to nucleophilic attack.²⁵ Of particular importance are the reactions of cyclic N-acyliminium ions with π -nucleophiles in carboncarbon bond-forming processes, with a great deal of attention given to cyclizations leading to alkaloids and other nitrogen-containing biologically active compounds.²⁵ These intramolecular α -amidoalkylations proceed stereoselectively²⁶ due to steric control by the substituents already present in the ring²⁷ or along the chain connect-ing the π -nucleophiles and the nitrogen atom.²⁸ In this paper, we detail our observations dealing with the intramolecular electrophilic aromatic substitution reaction of various hexahydroindolinones which are readily formed by the condensation of an appropriate amine with a (1-substituted-2-oxocyclohexyl)acetic acid derivative. To highlight the method, the above synthetic strategy was used to assemble (\pm) -erysotramidine (2).²⁹

Results and Discussion

The potential of using hexahydroindolinone derivatives for the synthesis of various erythrina alkaloids prompted us to first carry out some model studies to probe the likelihood of this approach for 1-azaspirocyclic ring assemblage. Our synthesis of the starting bicyclic lactam substrates follows a methodology similar to that previ-

(24) (a) Padwa, A.; Kappe, C. O.; Reger, T. S. J. Org. Chem. 1996, 61, 4888. (b) Padwa, A.; Hennig, R.; Kappe, C. O.; Reger, T. S. J. Org. Chem. 1998, 63, 1144. (c) Padwa, A.; Waterson, A. G. J. Org. Chem. 2000, 65, 235.

(25) For reviews of the chemistry of N-acyliminium ion cyclizations, see: (a) Speckamp, W. N.; Hiemstra, H. Tetrahedron 1985, 41, 4367. (b) Hiemstra, H.; Speckamp, W. N. In *The Alkaloids*; Academic Press: New York, 1988; Vol. 32, pp 271–339. (c) Hiemstra, H.; Speckamp, W. N. In Comprehensive Organic Synthesis; Trost, B. M., Fleming, I., Eds.; Pergamon Press: Oxford, 1991; Vol. 2, pp 1047-1082. (d) Speckamp, W. N.; Moolenaar, M. J. *Tetrahedron* **2000**, *56*, 3817. (e) Maryanoff, B. E.; Zhang, H. C.; Cohen, J. H.; Turchi, I. J.; Maryanoff,

Maryanon, B. E., Zhang, H. C., Cohen, S. H., Turrin, I. S., Maryanon, C. A. Chem. Rev. 2004, 104, 1431.
(26) de Koning, H.; Speckamp, W. N. In Stereoselective Synthesis [Houben-Weyl]; Helmchen, G., Hoffmann, R. W., Mulzer, J., Schaumann, E., Eds.; Thieme: Stuttgart, 1996; Workbench ed E21, Vol. 3, pp 1952-2010.

(27) For some recent examples, see: (a) Luker, T.; Koot, W. J.; Hiemstra, H.; Speckamp, W. N. J. Org. Chem. **1988**, 53, 220. (b) Padwa, A.; Heidelbaugh, T. M.; Kuethe, J. T.; McClure, M. S. J. Org. Chem. **1998**, 63, 6778. (c) Lee, Y. S.; Lee, J. Y.; Kim, D. W.; Park, H. *Tetrahedron* **1999**, 55, 4631. (d) Lee, Y. S.; Cho, D. J.; Kim, S. N.; Choi, J. H.; Park, H. J. Org. Chem. **1999**, 64, 9727. (e) Ducrot, P.; Thal, C. Tetrahedron Lett. 1999, 40, 9037. (f) Consonni, A.; Danieli, B.; Lesma, G.; Passarella, D.; Piacenti, P.; Silvani, A. Eur. J. Org. Chem. 2001, 1373. (g) Padwa, A. Pure Appl. Chem. 2003, 75, 47.

(28) For some representative examples, see: (a) Speckamp, W. N. Rec. Trav. Chim. Pays-Bas 1981, 345. (b) Maryanoff, B. E.; McComsey, D. F.; Duhl-Emswiler, B. A. J. Org. Chem. **1983**, 48, 5062. (c) Kano, S.; Yuasa, Y.; Yokomatsu, T.; Shibuya, S. J. Org. Chem. **1983**, 48, 3835. (d) Maryanoff, B. E.; McComsey, D. F.; Almond, H. R., Jr.; Mutter, M. S. J. Org. Chem. 1986, 51, 1341. (e) Ent, H.; Koning, H.; Speckamp,
 W. N. Heterocycles 1988, 27, 237. (f) Bahajaj, A. A.; Vernon, J. M.; Wilson, G. D. J. Chem. Soc., Perkin Trans. 1 2001, 1446. (g) Katritzky,

 (A. R.; Mehta, S.; He, H. Y. J. Org. Chem. **2001**, 66, 148.
 (29) Lee, H. I.; Cassidy, M. P.; Rashatasakhon, P.; Padwa, A. Org. Lett. 2003, 5, 5067.

^{(13) (}a) Mori, M.; Kuroda, S.; Zhang, C.; Sato, Y. J. Org. Chem. 1997, 62, 3263. (b) Uesaka, N.; Saitoh, F.; Mori, M.; Shibasaki, M.; Okamura, K.; Date, T. J. Org. Chem. 1994, 59, 5633. (c) Takano, S.; Inomata, K.; Ogasawara, K. Chem. Lett. 1992, 443.

⁽¹⁴⁾ Chawla, A. S.; Kapoor, V. K. In The Alkaloids: Chemical and Biological Perspectives; Pelletier, S. W., Ed.; Pergamon: 1995; Vol. 9, pp 86-153.

^{(22) (}a) Gervay, J. E.; McCapra, F.; Money, T.; Sharma, G. M. J. Chem. Soc., Chem. Commun. 1966, 142. (b) Tanaka, H.; Shibata, M.; Ito, K. Chem. Pharm. Bull. 1984, 32, 1578. (c) Chou, C. T.; Swenton, J. S. J. Am. Chem. Soc. 1987, 109, 6898.

^{(23) (}a) Mondon, A.; Ehrhardt, M. Tetrahedron Lett. 1966, 2557. (b) Haruna, M.; Ito, K. J. Chem. Soc., Chem. Commun. 1976, 345. (c) Ishibashi, H.; Sato, K.; Ikeda, M.; Maeda, H.; Akai, S.; Tamura, Y. J. Chem. Soc., Perkin Trans. 1 1985, 605. (d) Westling, M.; Smith, R.; Livinghouse, T. J. Org. Chem. 1986, 51, 1159. (e) Chikaoka, S.; Toyao, A.; Ogasawara, M.; Tamura, O.; Ishibashi, H. J. Org. Chem. 2003, 68, 312

SCHEME 1



ously described in the literature.³⁰ Condensation of the appropriate amine with a (1-substituted-2-oxocyclohexyl)acetic acid derivative (i.e., **4**) under Dean–Stark conditions in xylene at 160 °C for 1 h afforded the desired bicyclic lactams in high yield. The resulting aryl lactam precursors (i.e., **5** and **6**) were smoothly converted to the desired tetracyclic products in essentially quantitative yield when treated with either trifluoroacetic acid (**8**) or trifluoromethanesulfonic acid (**9**). The formation of a single lactam diastereomer is the result of the stereoelectronic preference for axial attack by the aromatic ring of the *N*-acyliminium ion (**7**) from the least hindered side (Scheme 1).³¹

10

11

A series of additional experiments showed that this electrophilic-induced cyclization succeeds with a variety of substrates containing tethered π -bonds. Thus, we were pleased to find that the analogous furanyl substituted hexahydroindolinone system **10** also underwent a related acid-induced cyclization to give the tetracyclic substituted lactam **11** in 78% yield (Scheme 2). This cyclization is especially noteworthy considering that none of the previously reported syntheses of the nonaromatic erythroidine alkaloids have employed this strategy of assemblage.³²

Because all of the previous examples involved aromatic π -bond cyclizations, we decided to study a hexahydroindolinone system that possesses a simple olefinic tether.



We found that treatment of the 3-methylbut-3-enylsubstituted lactam **12** with trifluoromethanesulfonic acid furnished a 3:1-mixture of octahydropyrido[2,1-*i*]indolones **13** and **14** in near quantitative yield. When the reaction was carried out in formic acid, the major product formed corresponded to formate **16** which was obtained as a 1:1 mixture of diastereomers. Formation of the above products can be nicely explained in terms of cyclization of the initially generated *N*-acyliminium ion onto the terminal π -bond to give carbocation **15** which subsequently reacts with HCO₂H to give **16** or else undergoes loss of a proton to produce **13** and **14** (Scheme 3).

20

Cationic cyclizations of alkynes have been exploited in a variety of transformations including polyene cyclizations³³ and reactions with *N*-acyliminium ³⁴ and iminium ions.³⁵ We found, however, that the annulative ring cyclization of *N*-but-3-ynylhexahydroindolinone **17** failed to give any discernible products. Since we had a sample of **17** on hand, we converted it to the corresponding vinyl enol ether **18** by reaction with HgCl₂ in methanol. We then conducted the acid-catalyzed reaction of **18** and found, somewhat to our surprise, that the cyclization gave rise to pyrrolo[3,2,1-*ij*]quinolinone **20** in 48% yield as a 1:1 mixture of diastereomers (Scheme 4). While the acidcatalyzed cyclization of **18** did not achieve its intended

^{(30) (}a) Ragan, J. A.; Claffey, M. C. *Heterocycles* **1995**, *41*, 57. (b) Ennis, M. D.; Hoffman, R. L.; Ghazal, N. B.; Old, D. W.; Mooney, P. A. J. Org. Chem. **1996**, *61*, 5813.

^{(31) (}a) Wilkens, H. J.; Traxler, F. Helv. Chim. Acta 1975, 58, 1512.
(b) Mondon, A.; Hansen, K. F.; Boehme, K.; Faro, H. P.; Nestler, H. J.; Vilhuber, H. G.; Böttcher, K. Chem. Ber. 1970, 103, 615. (c) Mondon, A.; Nestler, H. J. Chem. Ber. 1979, 112, 1329. (d) Dean, R. T.; Rapoport, H. A. J. Org. Chem. 1978, 43, 4183.

⁽³²⁾ The β -erythroidine skeleton has been prepared by an oxidative degradation of the aromatic ring (ring A) in erythrinans as the key step; see: Isobe, K.; Mohri, K.; Itoh, Y.; Toyokawa, Y.; Takeda, N.; Taga, J.; Hosoi, S.; Tsuda, Y. Chem. Pharm. Bull. **1992**, 40, 2632.

⁽³³⁾ Johnson, W. S.; Ward, C. E.; Boots, S. G.; Gravestock, M. B.; Markezich, R. L.; McCarry, B. E.; Okorie, D. A.; Parry, R. J. Am. Chem.. Soc. **1981**, *103*, 88.

⁽³⁴⁾ Schoemaker, H. E.; Boer-Terpstra, T.; Dijkink, J.; Speckamp, W. N. *Tetrahedron* **1980**, *36*, 143. Boer-Terpstra, T.; Dijkink, J.; Shoemaker, H. E.; Speckamp, W. N. *Tetrahedron Lett.* **1977**, 939.

 ⁽³⁵⁾ Overman, L. E.; Sharp, M. J. J. Am. Chem. Soc. 1988, 110, 612.
 Overman, L. E.; Sharp, M. J. Tetrahedron Lett. 1988, 29, 901.

SCHEME 5



SCHEME 6



purpose of providing access to keto-lactam **19** it did undergo a novel reductive cyclization.

Scheme 5 outlines a working mechanistic hypothesis to rationalize the formation of **20**. We surmise that the initial protonation takes place with the more nucleophilic enol ether π -bond and that the resulting carbocation **21** undergoes a subsequent cyclization on the enamido π -bond to furnish *N*-acyliminium ion **22**. The most obvious path available to **22** is proton loss thereby providing **23** as a transient and nondetectable intermediate. More than likely, under the acidic conditions, **23** suffers loss of methanol and the resulting iminium ion **24** reacts further by a hydride transfer from methanol to give **20**. In support of this proposal, we found that the yield of **20** could be significantly increased (93%) when the reaction of **18** was carried out using *p*-TsOH in the presence of Et₃SiH as the reducing agent.

To provide still additional evidence for the mechanistic proposal outlined in Scheme 5, we prepared the N-(3,3diethoxypropyl)-substituted hexahydroindolinone **25**. When **25** was treated with SnCl₄/Et₃SiH in toluene it reacted further to furnish pyrrolo[3,2,1-*ij*]quinolinone **27** in 85% yield (Scheme 6). The conversion of **25** into **27** undoubtedly proceeds via the intermediacy of **26** and this transformation provides good support for the mechanistic paradigm presented in Scheme 5.

A somewhat related cyclization reaction was also observed with the homologous acetal **28**. In this case, the product isolated in 82% yield corresponded to azepino-[3,2,1-*ji*]indolone **32**. A stepwise sequence of cyclizations with the eventual generation of intermediate **31** may be reasonably invoked (i.e., $\mathbf{28} \rightarrow \mathbf{29} \rightarrow \mathbf{30} \rightarrow \mathbf{31}$). With this system, loss of a proton from **31** to give **32** is apparently faster than bimolecular reduction with Et₃SiH (Scheme 7). This difference is probably related to the larger ring size present in **31**, which ultimately leads to a less strained π -bond in the final product. The same product (i.e., **32**) was formed in the absence of Et₃SiH.





SCHEME 8



At this point in our studies we became interested in determining what effect an alkyl substituent on the enamido π -bond would have on the Lewis acid promoted reaction. We were specifically interested in determining what would happen to the N-acyliminium ion (i.e., 34) derived from the cyclization of 33 since there is no possibility for proton loss. With this in mind, we treated the N-(3,3-diethoxypropyl)-7-ethyl-substituted hexahydroindolinone 33 with SnCl₄ in toluene, and this resulted in the formation of pyrrolo[3,2,1-ij]quinolinone 35 in 84% yield as a crystalline solid. The assignment of the stereochemistry of 35 was unequivocally established by an X-ray crystallographic study. The stereochemistry of the final product is the result of axial attack of water onto the thermodynamically most stable N-acyliminium ion intermediate (i.e., 34), and this takes place from the least hindered β -face (Scheme 8).

To further explore the scope and generality of these electrophilic-promoted cyclizations, we extended our studies to include the related hexahydro[1]pyrindinone **38** and 1*H*-quinolinone **39** systems. These compounds were prepared from the condensation of 2-(3,4-dimethoxyphenyl)ethylamine with either 3-(1-methyl-2-oxocyclopentyl) or 3-(1-methyl-2-oxocyclohexyl)propionic acid methyl ester (**36** or **37**) under Dean–Stark conditions. The resulting [6,5] and [6,6] lactams (i.e., **38** and **39**) were easily converted to the expected tetracyclic lactams **40** and **41** in 80% yield (Scheme 9). These two additional examples nicely demonstrate the facility with which the acid-induced cyclization cascade occurs using a variety of cyclic enamido lactams.

Encouraged by these results, we decided to apply the acid-catalyzed cyclization of hexahydroindolinones to the synthesis of erysotramidine (2) itself. To this end, bicyclic lactam 44 was prepared in 73% yield by condensation of 3,4-dimethoxyphenethylamine with ketoester 42 in the presence of TFA (Scheme 10). The formation of the α , β -unsaturated ene-amide 44 presumably involves initial generation of the expected hexahydroindolinone 43 followed by an acid-catalyzed elimination of the phenyl-

OMe

OMe

OMe

OMe

SeO₂/HCO₂H

50; R = CHO 51; R = H

49

OMe

)Me

DBU

Δ

KOH

Mel [R = H]

drobromination followed by isomerization of the π -bond into the thermodynamically most stable position. Ste-

reoselective allylic oxidation with selenium dioxide in the

presence of formic acid gave a 1:1 mixture of formate 50

and alcohol 51 in 60% yield (based on recovered starting

material) as single diastereomers. The stereochemical

outcome of the oxidation involves attack by the oxidant

from the least hindered α -position. Formate 50 was

quantitatively transformed into alcohol 51 by treatment

with acetyl chloride in ethanol.³⁷ Finally, compound 51

was converted into (\pm) -erysotramidine (2) in 91% yield

by O-methylation using KOH/MeI in THF according to

electrophilic aromatic substitution reaction of hexahy-

In summary, we have shown that the intramolecular

(37) Lee, Y. S.; Lee, J. Y.; Kim, D. W.; Park, H. Tetrahedron 1999,

(38) (a) Ito, K.; Suzuki, F.; Haruna, M. J. Chem. Soc., Chem.

Commun. 1978, 733. (b) Tsuda, Y.; Hosoi, S.; Katagiri, N.; Kaneko,

Tsuda's method (Scheme 12).³⁸

55, 4631.

1 2000, 1505.

SCHEME 9



sulfanyl group. With 44 in hand, we attempted to induce an acid-promoted cyclization but all of our efforts failed to produce any characterizable products, perhaps as a consequence of the antiaromatic character of the resulting cationic intermediate. Alternatively, the failure of 44 to cyclize might be a consequence of protonation alpha to the lactam carbonyl group. The resulting cationic species would be incapable of cyclization.³⁶

We were pleased to discover, however, that bicyclic lactam 44 underwent an extremely smooth cyclization to the desired erythrinan skeleton (i.e., 46) in 78% yield when treated with NBS in acetonitrile. It is of interest to note that this reaction is markedly dependent on the nature of the solvent and that acetonitrile is the only solvent used which favors cyclization (Scheme 11). Thus, when 44 was subjected to NBS in CH₂Cl₂, bromoenamide 47 was obtained in 87% yield and its formation can be attributed to a competitive deprotonation of the presumed

⁽³⁶⁾ This suggestion was made by one of the reviewers.

droindolinones allows for the rapid construction of the tetracyclic erythrinane skeleton. The cyclization reaction is also successful using variously substituted aryl-, furanyl-, and alkenyl-substituted bicyclic lactams under acidic conditions. The formation of the cyclized product as a single diastereomer is the result of the stereoelectronic preference for axial attack by the tethered π -bond onto the initially formed N-acyliminium ion from the least hindered side. The cyclization method was used to prepare (\pm)-erysotramidine. We expect that the total syntheses of other nonaromatic erythroidine alkaloids will also benefit from this general strategy. These investigations are currently underway and will be reported at some future date.

Experimental Section

General Procedure for the Preparation of Hexahydroindol-2-ones. To a 50 mL round-bottom flask equipped with a Dean–Stark trap and a reflux condensor was added (1methyl-2-oxo-cyclohexyl)acetic acid³⁹ (4) (5.0 mmol) and the appropriate primary amine (5.5 mmol) in 25 mL of xylene. The mixture was heated in an oil bath at 160 °C for 1 h during which time water was collected in the Dean–Stark trap. The solvent was removed by distillation, and the residue was purified by flash chromatography on silica gel using 50% ether/ hexane as the eluent.

1-[2-(3,4-Dimethoxyphenyl)ethyl]-3a-methyl-1,3,3a,4,5,6-hexahydroindol-2-one (5) was prepared in 84% from keto acid 4 and 3,4-dimethoxyphenethylamine: IR (neat) 1717, 1672, 1514, 1260, 1028 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.01 (s, 3H), 1.40–1.50 (m, 1H), 1.64–1.78 (m, 3H), 1.98–2.12 (m, 1H), 2.15 (d, 2H, J = 2.5 Hz), 2.16–2.24 (m, 1H), 2.65–2.80 (m, 2H), 3.31 (ddd, 1H, J = 14.3, 8.9, 5.7 Hz), 3.78 (s, 3H), 3.81 (s, 3H), 3.80–3.88 (m, 1H), 4.75 (t, 1H, J = 3.5 Hz), 6.67–6.75 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 18.4, 22.7, 26.0, 32.4, 33.9, 36.2, 40.4, 46.3, 55.9, 97.2, 111.2, 112.0, 120.8, 131.1, 145.5, 147.6, 148.8, 173.6; HRMS calcd for C₁₉H₂₅NO₃ 315.1834, found 315.1831.

3a-Methyl-1-phenethyl-1,3,3a,4,5,6-hexahydroindol-2one (6) was prepared in 93% from keto acid 4 and phenethylamine: IR (neat) 1718, 1682, 1454, 1407, 1314, 1164 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.08 (s, 3H), 1.44–1.56 (m, 1H), 1.71–1.81 (m, 3H), 2.02–2.23 (m, 2H), 2.21 (s, 2H), 2.75–2.90 (m, 2H), 3.38 (ddd, 1H, J = 14.3, 9.2, 5.7 Hz), 3.90 (ddd, 1H, J = 13.7, 9.2, 7.3 Hz), 4.79 (t, 1H, J = 3.5 Hz), 7.16–7.30 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 18.5, 22.8, 26.1, 33.0, 34.1, 36.3, 40.5, 46.4, 97.3, 126.6, 128.6, 129.0, 138.7, 145.7, 173.7; HRMS calcd for C₁₇H₂₁NO 255.1623, found 255.1622.

11,12-Dimethoxy-4a-methyl-1,2,3,4,4a,5,8,9-octahydroindolo[7a,1a]isoquinolin-6-one (8). To a solution of 0.05 g (0.16 mmol) of hexahydroindolone 5 in 3 mL of CH_2Cl_2 was added trifluoroacetic acid (0.04 mL, 0.48 mmol). The mixture was stirred at rt for 4 h, and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography to give the title compound 8 as a colorless oil in 94% yield: IR (neat) 1682, 1515, 1258, 1207, 1093 cm⁻¹;¹H NMR (400 MHz, CDCl₃) & 0.71 (s, 3H), 1.57-1.90 (m, 6H), 1.92 (d, 2H, J = 16.2 Hz); 2.20 (d, 1H, J = 13.6 Hz), 2.65 (dd, 1H, J = 15.9, 2.9 Hz), 2.82 (t, 1H, J = 9.5 Hz), 2.86 (t, 1H, J = 7.3Hz), 2.99 (ddd, 1H, J = 13.0, 13.0, 4.1 Hz), 3.84 (s, 3H), 3.86 (s, 3H), 4.24 (ddd, 1H, J = 13.0, 6.0, 1.6 Hz), 6.59 (s, 1H), 6.94 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.3, 21.5, 26.9, 29.1, 33.7, 34.2, 37.9, 40.5, 42.7, 55.9, 56.3, 64.1, 110.0, 112.2, 126.5, 131.6, 147.0, 147.6, 171.4; HRMS calcd for C₁₉H₂₅NO₃ 315.1834, found 315.1840.

4a-Methyl-1,2,3,4,4a,5,8,9-octahydroindolo[7a,1a]isoquinolin-6-one (9). A solution of hexahydroindolone 6 (0.08 g, 0.3 mmol) in 1 mL of trifluoromethanesulfonic acid was heated in a microwave reactor at 10 W, 60 $^{\circ}\mathrm{C},$ for 5 min. The mixture was diluted with ether (20 mL) and neutralized with a saturated solution of NaHCO₃. The organic layer was separated, dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel using 100% EtOAc as the eluent. The title compound 9 was obtained as a colorless oil in 88% yield (0.07 g): IR (neat) 1688, 1488, 1452, and 1307 cm $^{-1};\,^1\!\mathrm{H}$ NMR (400 MHz, CDCl₃) δ 0.69 (s, 3H), 1.55–1.98 (m, 7H), 1.92 (d, 1H, J = 16.3 Hz), 2.16–2.23 (m, 1H), 2.75 (ddd, 1H, J =15.9, 4.1, 1.6 Hz), 2.85 (d, 1H, J = 16.3 Hz), 2.90 (ddd, 1H, J = 15.9, 12.0, 6.0 Hz), 3.05 (tdd, 1H, J = 13.0, 4.4, 1.3 Hz), 4.23 (ddd, 1H, J = 13.0, 6.4, 2.2 Hz), 7.10-7.21 (m, 3H), 7.42-7.48 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 20.8, 21.3, 26.9, 29.5, 33.4, 34.2, 37.0, 40.4, 42.7, 64.4, 126.0, 126.4, 126.6, 130.0, 134.0, 139.6, 171.5; HRMS calcd for C17H21NO 255.1623, found 255.1616.

1-(2-Furan-2-ylethyl)-3a-methyl-1,3a,4,5,6-hexahydroindol-2-one (10) was prepared in 65% yield from keto acid 4 and 2-furan-2-yl-ethylamine: IR (thin film) 2860, 1674, 1449, 1072 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.12 (s, 3H), 1.51 (m, 1H), 1.73–1.77 (m, 3H), 2.10–2.23 (m, 4H), 2.87 (t, 2H, J = 7.2 Hz), 3.45 (m, 1H), 3.93 (m, 1H), 4.77 (t, 1H, J = 3.2 Hz), 6.06 (t, 1H, J = 2.4 Hz), 6.26 (t, 1H, J = 2.0 Hz), 7.30 (t, 1H, J = 1.2 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 18.5, 22.8, 25.6, 26.1, 34.1, 36.3, 37.9, 46.4, 97.3, 106.5, 110.4, 141.5, 145.4, 152.7, 173.8; HRMS calcd for C₁₅H₁₉NO₂ 245.1416, found 245.1411.

1,2-Furo[3,2-c]-7a-methyl-3,4,7,7a,8,9,10,11-octahydropyrido[2,1-*i*]indol-6-one (11). To a solution of 0.31 g (1.3 mmol) of hexahydroindolone 10 in 13 mL of CH_2Cl_2 was added trifluoroacetic acid (0.3 mL, 3.8 mmol). The mixture was stirred at rt for 4 h, and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography on silica gel using EtOAc as the eluent. The title compound $11\ \mathrm{was}$ obtained as a colorless oil in 78%yield: IR (thin film) 2861, 1687, 1452, 1416, 1327 cm⁻¹;¹H NMR (400 MHz, CDCl₃) δ 0.72 (s, 3H), 1.47–1.58 (m, 4H), 1.71–1.78 (m, 3H), 1.90 (d, 1H, J = 16.4 Hz), 2.10 (m, 1H), 2.70 (m, 2H), 2.79 (d, 1H, J = 16.4 Hz), 3.01 (dddd, 1H, J = 16.4 Hz)24.4, 11.2, 6.0, 1.6 Hz), 4.38 (ddd, 1H, J = 12.6, 6.0, 1.6 Hz), 6.38 (d, 1H, J = 1.6 Hz), 7.30 (d, 1H, J = 1.6 Hz); ¹³C NMR $(100 \; MHz, CDCl_3) \, \delta \; 21.9, 22.1, 23.4, 26.5, 33.7, 33.8, 36.5, 40.2,$ 42.1, 63.9, 108.5, 119.9, 141.3, 147.8, 172.3; HRMS calcd for C₁₅H₁₉NO₂ 245.1416, found 245.1406.

3a-Methyl-1-(3-methylbut-3-enyl)-1,3,3a,4,5,6-hexahydroindol-2-one (12) was prepared in 81% yield from keto acid 4 and 3-methylbut-3-enylamine: IR (neat) 1717, 1679, 1619, 1454, 1406, 1318 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.14 (s, 3H), 1.44–1.56 (m, 1H), 1.70–1.81 (m, 3H), 1.75 (s, 3H), 2.02–2.14 (m, 1H), 2.17–2.27 (m, 3H), 2.21 (s, 2H), 3.22 (dt, 1H, J = 13.7, 6.7 Hz), 3.80 (dt, 1H, J = 13.7, 8.3 Hz), 4.68 (s, 1H), 4.74 (s, 1H), 4.76 (t, 1H, J = 3.5 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 18.6, 22.4, 22.9, 26.3, 34.1, 34.7, 36.3, 37.4, 46.5, 97.1, 112.3, 142.7, 145.7, 173.8; HRMS calcd for C₁₄H₂₁NO 219.1623, found 219.1620.

2,7a-Dimethyl-3,4,7,7a,8,9,10,11-octahydropyrido[**2,1**-*i*]**indol-6-one (13).** A solution of hexahydroindolone **12** (0.2 g, 0.9 mmol) in 1 mL of trifluoromethanesulfonic acid was stirred at rt for 2 h. The mixture was diluted with ice–water (20 mL) and neutralized with a saturated solution of NaHCO₃. After extraction with ether, the organic layer was combined, dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel using 50% ether in hexane as the eluent to give a 3:1 mixture of lactams **13** and **14**. Compound **13** was obtained pure in 75% yield (0.14 g) as a white solid: mp 77–79 °C; IR (KBr) 1688, 1452, 1422, 1307 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 0.78 (s, 3H), 1.15–1.42 (m, 4H), 1.52–1.65 (m, 3H), 1.68 (s, 3H), 1.77 (d, 1H, J = 16.0 Hz), 1.83 (dd, 1H, J = 16.8, 4.8 Hz), 1.91 (dq, 1H, J = 13.0, 2.8 Hz), 2.02–2.14 (m,

⁽³⁹⁾ Asselin, A. A.; Humber, L. G.; Dobson, T. A.; Komlossy, J.; Martel, R. R. J. Med. Chem. **1976**, 19, 787.

1H), 2.63 (d, 1H, J = 16.0 Hz), 2.80 (ddd, 1H, J = 13.0, 11.8, 4.8, 1.3 Hz), 4.03 (ddd, 1H, J = 13.0, 6.7, 0.6 Hz), 5.49 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 22.0, 22.2, 23.9, 25.7, 29.2, 33.4, 33.6, 36.0, 40.3, 42.4, 62.6, 121.7, 132.3, 172.0; HRMS calcd for C₁₄H₂₁NO 219.1623, found 219.1631.

2,7a-Dimethyl-1,4,7,7a,8,9,10,11-octahydropyrido[**2,1**-*i*]**indol-6-one** (**14**) was obtained from the chromatographic separation in 25% yield (0.05 g) as a white solid: mp 49–52 °C; IR (KBr) 1697, 1669, 1438, 1394 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.06 (s, 3H), 1.20–1.59 (m, 8H), 1.64 (s, 3H), 1.78–1.86 (m,1H), 2.12 (s, 2H), 2.16–2.26 (m, 1H), 3.19–3.28 (m, 1H), 4.26–4.35 (m, 1H), 5.29 (brs, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 20.1, 21.9, 22.2, 24.1, 29.2, 36.0, 36.4, 37.9, 38.2, 45.1, 61.6, 117.1, 131.8, 175.1; HRMS calcd for C₁₄H₂₁NO 219.1623, found 219.1631.

Formic Acid 2,7a-Dimethyl-6-oxodecahydropyrido-[2,1-*i*]indol-2-yl Ester (16). A solution of hexahydroindolone 12 (0.1 g, 0.46 mmol) in 2 mL of anhydrous formic acid was stirred at rt for 5 h. The mixture was diluted with water (20 mL) and neutralized with a saturated solution of NaHCO₃. After extraction with ether, the organic layer was combined, dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel using ether as the eluent. A 1:1 mixture of the two diastereomers of 16 was obtained as the major product in 58% yield. The minor product (15%) was identified as 2,-7a-dimethyl-3,4,7,7a,8,9,10,11-octahydropyrido[2,1-*i*]indol-6one (13).

The title compound **16** showed the following spectral properties: IR (neat) 1721, 1687, 1445, 1411, 1135 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 0.99 and 1.00 (s, 3H), 1.25–1.50 (m, 5H), 1.52 and 1.69 (s, 3H), 1.53–1.61 (m, 2H), 1.70–1.77 (m, 1H), 1.82–1.90 (m, 2H), 1.95 and 2.09 (d, 2H, J = 14.8 Hz), 2.12 and 2.45 (dd, 1H, J = 14.8, 1.4 Hz), 2.36 (m, 1H), 2.82 (dt, J = 14.3, 7.1 Hz) and 2.90 (ddd, J = 13.8, 13.8, 1.9 Hz) (1H), 3.90 (ddd, J = 13.8, 5.2, 1.9 Hz) and 3.94 (dt, J = 14., 5.2 Hz) (1H), 7.88 and 8.00 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.5, 21.6, 21.7, 21.8, 23.2, 23.5, 26.2, 28.0, 30.2, 32.7, 33.1, 34.3, 34.5, 35.1, 35.3, 35.7, 36.2, 39.1, 39.2, 39.7, 43.4, 43.6, 62.3, 81.5. 82.4, 160.2, 160.8, 174.7; HRMS calcd for C₁₅H₂₃NO₃ 265.1678, found 265.1685.

1-But-3-ynyl-3a-methyl-1,3,3a,4,5,6-hexahydroindol-2one (17) was prepared in 67% yield from (1-methyl-2-oxocyclohexyl)acetic acid (4) and but-3-ynylamine: IR (neat) 1720, 1678, 1405, 1314, 1169 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.14 (s, 3H), 1.42–1.53 (m, 1H), 1.68–1.80 (m, 3H), 1.92 (t, 1H, J = 2.1 Hz), 2.00–2.19 (m, 2H), 2.20 (s, 2H), 2.33–2.43 (m, 2H), 3.30 (ddd, 1H, J = 13.9, 7.6, 6.0 Hz), 3.80 (dt, 1H, J= 15.9, 7.6 Hz), 4.77 (t, 1H, J = 3.8 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 16.7, 18.5, 22.7, 26.2, 33.9, 36.4, 37.8, 46.3, 70.0, 81.0, 97.4, 145.2, 173.8; HRMS calcd for C₁₃H₁₇NO 203.1310, found 203.1308.

1-(3-Methoxybut-3-enyl)-3a-methyl-1,3,3a,4,5,6-hexahydroindol-2-one (18). To a solution of the above but-3ynylhexahydroindolone 17 (0.37 g, 1.8 mmol) and NEt_3 (0.4 mL, 2.7 mmol) in anhydrous methanol (10 mL) was added HgCl₂ (0.37 g, 1.4 mmol). The suspension was stirred vigorously under reflux for 4 h. The solvent was removed under reduced pressure, and the residue was diluted with ether. The precipitate that formed was removed by filtration, and the filtrate was concentrated under reduced pressure. The crude oil was purified by flash chromatography on silica gel using 50% of ether in hexane with 3% NEt_3 as the eluent. The title compound 18 was obtained as a colorless oil in 63% yield (0.27 g): IR (neat) 1724, 1677, 1403, 1314, 1083 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.14 (s, 3H), 1.45–1.55 (m, 1H), 1.70–1.80 (m, 3H), 2.01–2.13 (m, 1H), 2.15–2.35 (m, 3H), 2.21 (s, 2H), 3.30 (ddd, 1H, J = 14.0, 7.4, 6.4 Hz), 3.48 (s, 3H), 3.78 (dt, 1H, J = 14.0, 7.4, 6.4 Hz) 14.0, 7.4 Hz), 3.86 (s, 2H), 4.78 (t, 1H, J = 3.5 Hz); ¹³C NMR (100 MHz, CDCl₃) & 18.6, 22.8, 26.3, 32.6, 34.1, 36.3, 37.3, 46.5, 54.9, 82.5, 97.0, 145.7, 161.0, 173.8; HRMS calcd for C₁₄H₂₁-NO₂ 235.1572, found 235.1568.

6,9a-Dimethyl-5,6,7,8,9,9a-hexahydro-1H,4H-pyrrolo-[3,2,1-ij]quinolin-2-one (20). To a solution of the above enol ether 18 (0.12 g, 0.5 mmol) in CH₂Cl₂ (5 mL) at 0 °C was slowly added trifluoroacetic acid (0.12 mL, 1.5 mmol). The mixture was allowed to warm to rt, stirred for 2 h, and concentrated under reduced pressure. The crude product was purified by flash chromatography using 50% ether in hexane as the eluent. The title compound was obtained as a 1:1 mixture of diastereomers: IR (neat) 1728, 1690, 1404, 1365, 1312 $\rm cm^{-1}; ^1H$ NMR (400 MHz, CDCl₃) δ 0.92 and 0.96 (d, 3H, J = 7.1 Hz), 1.08-1.10 (s, 3H), 1.34-1.50 (m, 2H), 1.63-1.75 (m, 3H), 1.77-2.08 (m, 3H), 2.12–2.21 (m, 3H), 3.14 (td, 1H, J = 13.8, 3.8 Hz) and 3.25 (ddd, 1H, J = 12.4, 8.1, 4.3 Hz), 3.60 (ddd, 1H, J = 12.4, 8.1, 4.8 Hz) and 3.72 (dt, 1H, J = 12.9, 4.8 Hz); $^{13}\mathrm{C}$ NMR (100 MHz, CDCl₃) δ 17.9, 18.7, 18.8, 19.9, 24.1, 24.9, 25.8, 28.8, 29.5, 29.8, 30.0, 33.9, 34.0, 35.1, 35.2, 35.4, 36.9, 46.8, 47.2, 110.8, 111.3, 137.9, 138.1, 172.7, 172.9; HRMS calcd for C₁₃H₁₉-NO 205.1467, found 205.1474.

1-(3,3-Diethoxypropyl)-3a-methyl-1,3,3a,4,5,6-hexahydroindol-2-one (25) was prepared in 76% yield from keto acid 4 and 3,3-diethoxypropylamine: IR (neat) 1722, 1680, 1408, 1129, 1061 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.16 (t, 3H, J = 7.0 Hz), 1.17 (t, 3H, J = 7.0 Hz), 1.21 (s, 3H), 1.43–1.55 (m, 1H), 1.66–1.90 (m, 5H), 2.06 (dtd, 1H, J = 17.8, 8.6, 3.5 Hz), 2.12–2.20 (m, 1H), 2.19 (s, 2H), 3.21 (ddd, 1H, J = 14.0, 83, 5.7 Hz), 3.38–3.50 (m, 2H), 3.55–3.72 (m, 3H), 4.45 (t, 1H, J = 5.7 Hz), 4.77 (t, 1H, J = 3.5 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 15.5, 18.5, 22.8, 26.1, 31.4, 34.0, 35.4, 36.3, 46.4, 61.6, 61.8, 97.3, 101.3, 145.7, 173.7; HRMS calcd for C₁₆H₂₇NO₃ 281.1991, found 281.1986.

9a-Methyl-5,6,7,8,9,9a-hexahydro-1H,4H-pyrrolo[3,2,1*ij*]quinolin-2-one (27). To a solution of the above acetal 25 (1.0 mmol) in 10 mL of anhydrous toluene cooled in an ethylene glycol-CO₂ bath were added Et₃SiH (0.16 mL, 1.0 mmol) and SnCl₄ (0.12 mL, 1.0 mmol). The solution was allowed to warm to rt, stirred for 1 h, and then quenched by the addition of 10 mL of water. The mixture was extracted with ether, and the combined organic phase was dried over MgSO₄, filtered, and concentrated. The crude product was purified by flash chromatography on silica gel using 50% ether/hexane as the eluent to give 27 in 85% yield: IR (neat) 1691, 1676, 1456, 1409, and 1366 cm^{-1,1}H NMR (400 MHz, CDCl₃) δ 1.15 (s, 3H), 1.40– 1.51 (m, 1H), 1.60–2.09 (m, 9H), 2.22 (dd, 2H, J = 20, 15.9 Hz), 3.19 (ddd, 1H, J = 13.0, 9.5, 3.2 Hz), and 3.77 (dt, 1H, J = 13.0, 5.1 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 18.9, 21.6, 25.5, 25.7, 27.0, 34.2, 35.3, 38.8, 47.2, 106.8, 138.8, 173.1. Anal. Calcd for C₁₂H₁₇NO: C, 75.35; H, 8.96; N, 7.32. Found: C, 75.10; H, 9.00; N, 7.20.

1-(4,4-Diethoxybutyl)-3a-methyl-1,3,3a,4,5,6-hexahydroindol-2-one (28) was prepared in 75% from keto acid **4** and 4,4-diethoxybutylamine: IR (neat) 1720, 1677, 1401, 1127, 1063 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.15 (s, 3H), 1.18 (t, 6H, J = 7.0 Hz), 1.45–1.82 (m, 8H), 2.08 (dtd, 1H, J = 17.8, 8.6, 3.5 Hz), 2.16–2.22 (m, 1H), 2.22 (s, 2H), 3.14–3.24 (m, 1H), 3.46 (dq, 2H, J = 9.5, 7.3 Hz), 3.56–3.67 (m, 3H), 4.47 (t, 1H, J = 3.5 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 15.5, 18.5, 22.2, 22.8, 26.3, 31.1, 34.1, 36.3, 39.0, 46.5, 61.2, 61.5, 97.2, 102.6, 145.8, 173.9; HRMS calcd for C₁₇H₂₉-NO₃ 295.2147, found 295.2144.

10a-Methyl-4,5,8,9,10,10a-hexahydro-1H-azepino[3,2,1*hi*]**indol-2-one (32).** To a solution of the above acetal **28** (1.0 mmol) in 10 mL of anhydrous toluene cooled in an ethylene glycol $-CO_2$ bath were added Et₃SiH (0.16 mL, 1.0 mmol) and SnCl₄ (0.12 mL, 1.0 mmol). The solution was allowed to warm to rt, stirred for 1 h, and then quenched by the addition of 10 mL of water. The mixture was extracted with ether, and the combined organic phase was dried over MgSO₄, filtered, and concentrated. The crude product was purified by flash chromatography on silica gel using 50% ether/hexane as the eluent to give **32** in 82% yield: IR (neat) 1716, 1662, 1615, 1363, 1173 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.14 (s, 3H), 1.41–1.52 (m, 1H), 1.69–1.82 (m, 3H), 2.10–2.33 (m, 3H), 2.25 (d, 2H, J = 1.9 Hz), 2.47 (dddd, 1H, J = 16.8, 7.0, 5.4, 1.3 Hz), 2.93 (dd, 1H, J = 13.0, 9.5 Hz), 4.26 (ddd, 1H, J = 13.0, 5.4, 2.9 Hz), 5.56 (dd, 1H, J = 11.4, 1.9 Hz), 5.71 (ddd, 1H, J = 11.4, 7.6, 4.1 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 18.7, 26.1, 29.3, 30.2, 33.6, 37.7, 41.0, 46.7, 108.4, 128.5, 129.3, 143.9, 173.4; HRMS calcd for C₁₃H₁₇NO 203.1310, found 203.1312.

1-(3,3-Diethoxypropyl)-7-ethyl-3a-methyl-1,3,3a,4,5,6hexahydroindol-2-one (33). A mixture of 1-(3,3-diethoxypropyl)-3a-methyl-7-vinyl-1,3,3a,4,5,6-hexahydroindol-2-one⁴⁰ (0.35 g, 1.14 mmol) and 10% of palladium on charcoal (0.05 g) in absolute ethanol (10 mL) was stirred at rt in a flask equipped with a balloon of hydrogen gas. After being stirred for 20 h, the mixture was filtered through a pad of Celite, and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography on silica gel using a 50% ether /hexane mixture as the eluent. The title compound 33 was obtained in 83% yield (0.29 g) as a colorless oil: IR (neat) 1714, 1676, 1371, 1133, 1061 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 0.98 (t, 3H, J = 7.6 Hz), 1.05 (s, 3H) 1.18 (t, 3H, J = 7.0 Hz), 1.19 (t, 3H, J = 7.0 Hz), 1.36-1.48 (m, 1H), 1.60-2.16 (m, 8H), 2.12 (d, 1H, J = 15.6 Hz), 2.20 (d, 1H, J = 15.6 Hz)15.6 Hz), 3.32-3.55 (m, 4H), 3.59-3.72 (m, 2H), 3.99 (ddd, 1H, $J = 14.0, 10.2, 6.0 \text{ Hz}), 4.51 (t, 1\text{H}, J = 5.7 \text{ Hz}); {}^{13}\text{C} \text{ NMR} (100)$ MHz, CDCl₃) δ 13.3, 15.5, 18.8, 24.7, 25.5, 29.3, 32.2, 34.6, 38.5, 39.1, 47.0, 61.7, 62.4, 101.5, 115.5, 137.8, 175.4; HRMS calcd for C₁₈H₃₁NO₃ 309.2304, found 309.2312.

6-Ethoxy-6a-ethyl-9b-hydroxy-9a-methyloctahydropyrrolo[3,2,1-ij]quinolin-2-one (35). To a solution of the above acetal **33** (0.29 g, 0.94 mmol) in 10 mL of anhydrous toluene cooled in an ethylene glycol– CO_2 bath was added $SnCl_4$ (0.11 mL, 0.94 mmol). The solution was allowed to warm to rt, stirred for 2 h, and then quenched by the addition of 10 mL of water. The mixture was extracted with ether, and the combined organic phases were dried over MgSO₄, filtered, and concentrated. The crude product was purified by flash chromatography on silica gel using 50% ether/hexane as the eluent. The title compound 35 was obtained as a white solid in 84% yield (0.22 g): mp 131-133 °C; IR (KBr) 1690, 1454, 1398, 1098, 1067 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 0.76 (t, 3H, J = 7.1 Hz), 1.08 (s, 3H), 1.22 (t, 3H, J = 6.7 Hz), 1.30 (dddd, 1H, J = 14.8, 14.8, 7.6, 1.9 Hz), 1.39 (dt, 1H, J = 8.6, 13.3 Hz), 1.54 (dt, 1H, J = 13.8, 3.8 Hz), 1.57-1.72 (m, 4H), 1.75-1.88 (m, 3H), 1.89–1.99 (m, 1H), 2.26 (d, 1H, J = 16.9 Hz), 2.32 (d, 1H, J = 16.9 Hz), 3.16 (ddd, 1H, J = 13.3, 13.3, 4.8 Hz), 3.36 (ddt, 1H, J = 9.1, 7.1, 7.1 Hz), 3.49 (t, 1H, J = 2.9 Hz), 3.67 (ddt, 1H, J = 9.1, 7.1, 7.1 Hz), 3.94 (dd, 1H, J =13.3, 6.2 Hz), 6.56 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 7.7, 15.5, 17.4, 19.9, 22.4, 26.0, 26.6, 31.5, 33.5, 38.9, 44.4, 48.9, 66.7, 78.8, 92.8, 171.6. Anal. Calcd for C₁₆H₂₇NO₃: C, 68.29; H, 9.67; N, 4.98. Found: C, 68.57; H, 9.77; N, 4.96.

The structure of **35** was unequivocally established by an X-ray crystallographic study.

1-[2-(3,4-Dimethoxyphenyl)ethyl]-4a-methyl-1,3,4,4a,5,6-hexahydro[1]pyrindin-2-one (38) was prepared in 41% yield from 3-(1-methyl-2-oxocyclopentyl)propionic acid methyl ester (**36**) and 2-(3,4-dimethoxyphenyl)ethylamine: IR (neat) 1664, 1631, 1514, 1261, 1235, 1029 cm⁻¹;¹H NMR (400 MHz, CDCl₃) δ 1.04 (s, 3H), 1.60–1.70 (m, 2H), 1.73–1.86 (m, 2H), 2.27 (ddd, 1H, J = 15.6, 8.9, 3.2 Hz), 2.41–2.64 (m, 3H), 2.75 (t, 2H, J = 8.6 Hz), 3.66 (dt, 1H, J = 13.3, 7.9 Hz), 3.83 (s, 3H), 3.85 (s, 3H), 3.90 (dt, 1H, J = 13.3, 7.9 Hz), 4.78 (t, 1H, J = 2.2 Hz), 6.69–6.79 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 21.1, 28.4, 29.7, 32.8, 33.1, 39.6, 42.7, 45.1, 56.0, 101.7, 111.3, 112.2, 120.9, 131.7, 147.3, 147.7, 149.0, 168.7; HRMS calcd for C₁₉H₂₅NO₃ 315.1834, found 315.1842.

1-[2-(3,4-Dimethoxyphenyl)ethyl]-4a-methyl-3,4,4a,5,6,7hexahydro-1*H*-quinolin-2-one (39). In a 10 mL reaction tube were placed 3-(1-methyl-2-oxocyclohexyl)propionic acid methyl ester (37) (1.0 mmol), 2-(3,4-dimethoxyphenyl)ethylamine (3.0 mmol), and xylene (1.0 mL). The reaction vessel was heated in a microwave reactor at 150 W at 160 °C for 5 h. The reaction mixture was allowed to cool to rt, and the crude product was purified by flash silica gel chromatography using a 50% ether in hexane mixture as the eluent. The title compound 39 was obtained in 67% yield as a colorless oil: IR (neat) 1663, 1636, 1514, 1261, 1233, 1158, 1028 $\rm cm^{-1}, ^{1}H$ NMR (400 MHz, CDCl_3) δ 1.03 (s, 3H), 1.37–1.47 (m, 1H), 1.52– 1.70 (m, 5H), 2.05-2.16 (m, 1H), 2.17-2.27 (m, 1H), 2.46-2.60 (m, 2H), 2.68 (ddd, 1H, J = 13.3, 9.5, 7.3 Hz), 2.81 (ddd, 1H, J = 13.3, 9.5, 7.3 Hz), 3.80–3.88 (m, 2H), 3.83 (s, 3H), 3.86 (s, 3H), 5.13 (dd, 1H, J = 5.1, 2.5 Hz), 6.73-6.79 (m, 3H);¹³C NMR (100 MHz, CDCl₃) δ 17.9, 22.9, 24.9, 29.3, 32.5, 33.1, 34.2, 38.2, 45.1, 56.0, 105.0, 111.3, 112.1, 120.7, 130.9, 142.1, 147.6, 148.9, 168.5; HRMS calcd for C₂₀H₂₇NO₃ 329.1991, found 329.1988

8,9-Dimethoxy-13a-methyl-1,2,5,6,11,12,13,13a-octahydrocyclopenta[2,3]pyrido-[2,1-a]isoquinolin-3-one (40). To a solution of 0.05 g (0.16 mmol) of hexahydro[1]pyrindin-2-one 38 in 1.0 mL of CH₂Cl₂ was added trifluoroacetic acid (0.1 mL). The mixture was stirred at rt for 16 h, and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography to give 40 as a white solid in 80% yield (0.04 g): mp 118-120 °C; IR (neat) 1633, 1516, 1407, 1258, 1217 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 0.78 (s, 3H), 1.47 (dt, 1H, J = 12.9, 3.3 Hz), 1.93–2.18 (m, 4H), 2.20-2.35 (m, 2H), 2.37-2.52 (m, 4H), 2.66 (ddd, 1H, J = 14.3, 12.4, 1.9 Hz), 2.88 (ddd, 1H, J = 16.2, 12.4, 4.3 Hz), 3.83 (s, 6H), 4.87 (dd, 1H, J = 11.9, 3.8 Hz), 6.55 (s, 1H), 6.80 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 20.8, 21.5, 29.1, 29.9, 34.1, 39.9, 42.0, 42.5, 44.5, 55.9, 56.2, 73.7, 110.5, 111.8, 129.0, 133.6, 147.1, 147.3, 168.9. Anal. Calcd for C₁₉H₂₅NO₃: C, 72.35; H, 7.99; N, 4.44. Found: C, 72.31; H, 8.04; N, 4.35.

7,8-Dimethoxy-13a-methyl-1,4,5,10,11,12,13,13a-octahydro-2H-3a-azabenzo[d]phenanthren-3-one (41). To a solution of hexahydro-1*H*-quinolinone **39** (0.2 g, 0.6 mmol) in 6.0 mL of CH₂Cl₂ was added several drops of trifluoromethanesulfonic acid, and the mixture was stirred at rt for 2 h. The mixture was diluted with ice-water (20 mL) and neutralized with a saturated solution of NaHCO₃. After extraction with ether, the organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel using ether as the eluent to give 41 in 80% yield (0.16 g) as a white solid: mp 143-144 °C; IR (KBr) 1631, 1514, 1409, 1258, 1218 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 0.62 (s, 3H), 1.14–1.20 (m, 1H), 1.57 (d, 1H, J = 14.8 Hz), 1.68–1.82 (m, 3H), 1.88–2.00 (m, 2H), 2.22-2.38 (m, 2H), 2.42-2.56 (m, 4H), 2.80-2.90 (m, 2H), 3.84 (s, 3H), 3.85 (s, 3H), 4.85-4.92 (m, 1H), 6.57 (s, 1H), 7.35 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 19.7, 21.9, 23.6, 28.6, 30.0, 30.1, 35.8, 36.1, 37.0, 38.4, 55.6, 56.3, 65.8, 112.1, 112.3, 130.1, 132.4, 145.8, 147.1, 168.4. Anal. Calcd for $\mathrm{C_{20}H_{27}NO_{3}}{:}$ C, 72.92; H, 8.26; N, 4.25. Found: C, 72.70; H, 8.24; N, 4.26.

(2-Oxo-1-phenylthiocyclohexyl)acetic Acid Ethyl Ester (42). To a solution containing 2.1 g (10.2 mmol) of 2-phenythiocyclohexanone⁴¹ in 30 mL of THF was added 0.45 g (11.2 mmol) of NaH at 0 °C. The reaction mixture was allowed to warm to room temperature and was stirred for 1 h. The resulting mixture was added to 1.87 g (11.2 mmol) of ethyl bromoacetate at room temperature. The solution was stirred for 8 h at 25 °C and was quenched by the addition of water. The mixture was extracted with EtOAc, and the combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. Purification of the residue by silica gel column chromatography provided 2.4 g (82%) of keto ester **42** as a colorless oil: IR (neat) 2937, 1733, 1701 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.21 (t, 3H, J

⁽⁴⁰⁾ Hexahydroindolinone **33** was prepared by the selective bromination of **28** followed by a palladium-catalyzed cross-coupling reaction with vinyl tributyltin and a subsequent catalytic hydrogenation of the vinyl group. Details of the procedure are described in the Supporting Information.

⁽⁴¹⁾ Coates, R. M.; Pigott, H. D.; Ollinger, J. Tetrahedron Lett. 1974, 15, 3955.

= 7.2 Hz), 1.72–1.89 (m, 2H), 2.05–2.21 (m, 3H), 2.40 (ddd, 1H, J = 13.3, 4.0, 2.4 Hz), 2.47 (d, 1H, J = 16.8 Hz), 2.48–2.59 (m, 1H), 2.86 (d, 1H, J = 16.8 Hz), 3.21 (ddd, 1H, J = 15.3, 13.6, 6.0 Hz), 4.07 (dq, 2H, J = 7.2, 2.8 Hz), 7.29–7.40 (m, 5H); ¹³C NMR (CDCl₃, 100 MHz) δ 14.1, 21.3. 26.0, 36.3, 37.3, 40.7, 58.0, 60.4, 129.0, 129.4, 129.9, 136.9, 170.7, 204.8; HRMS calcd for C₁₆H₂₀O₃SLi (M + Li⁺) 299.1293, found 299.1289.

1-[2-(3,4-Dimethoxyphenyl)ethyl]-1,4,5,6-tetrahydroindol-2-one (44). To a solution containing 2.3 g (7.9 mmol) of 42 in 16 mL of toluene at room temperature was added 2.1 g (11.8 mmol) of 3,4-dimethoxyphenethylamine. The reaction mixture was heated at reflux for 3 h and then cooled to room temperature. To the resulting mixture was added 1.35 g (11.8 mmol) of trifluoroacetic acid at 25 °C, and the solution was heated at reflux for an additional 48 h. After cooling, 30 mL of water was added to the reaction mixture. The mixture was extracted with EtOAc, and the combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. Purification of the residue by silica gel column chromatography provided 1.7 g (73%) of ene-amide 44as a yellow pale oil: IR (neat) 2832, 1689, 1515 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.79 (m, 2H), 2.28 (dt, 2H, $J=5.6,\,4.8$ Hz), 2.60 (dt, 2H, J = 6.8, 1.6 Hz), 2.80 (t, 2H, J = 7.6 Hz), 3.73 (t, 2H, J = 7.6 Hz), 3.85 (s, 6H), 5.47 (dt, 1H, J = 4.8, 1.6 Hz), 5.74 (d, 1H, J = 1.6 Hz), 6.69 (d, 1H, J = 1.6 Hz), 6.74 (dd, 1H, J = 8.4, 1.6 Hz), 6.79 (d, 1H, J = 8.4 Hz); ¹³C NMR (CDCl₃, 100 MHz) & 23.4, 24.2, 24.5, 34.7, 40.6, 55.77, 55.83, 110.0, 111.1, 112.0, 115.6, 120.6, 131.4, 139.7, 147.1, 147.5, 148.7, 170.1; HRMS calcd for $C_{18}H_{21}NO_3Li (M + Li^+) 306.1681$, found 306.1673.

1-Bromo-11,12-dimethoxy-1,2,3,4,8,9-hexahydroindolo-[7a,1a]isoquinolin-6-one (46). To a solution containing 1.2 g (4.0 mmol) of 44 in 400 mL of acetonitrile was added 0.78 g (4.4 mmol) of NBS at 25 °C. The reaction mixture was stirred for 3 h at 25 °C, and the solvent was removed under reduced pressure. The mixture was quenched by the addition of water and extracted with EtOAc, and the combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. Purification of the residue by silica gel column chromatography provided 1.18 g (78%) of the cyclized product 46 as a white solid: mp 133-135 °C; IR (neat) 2934, 1686, 1509 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.96- $2.27\,({\rm m},\,4{\rm H}),\,2.80-2.92\,({\rm m},\,1{\rm H}),\,3.01\,({\rm t},\,2{\rm H},\,J=7.2\,{\rm Hz}),\,2.94-2.92\,({\rm m},\,2{\rm Hz}),$ 3.08 (m, 1H), 3.56 (dt, 1H, J = 12.4, 7.2 Hz), 3.87 (s, 3H), 3.82-3.92 (m, 1H), 4.68 (brs, 1H), 3.88 (s, 3H), 6.10 (d, 1H, J = 1.6)Hz), 6.75 (s, 1H), 7.00 (s, 1H); $^{13}\mathrm{C}$ NMR (CDCl₃, 100 MHz) δ 21.4, 27.4, 28.8, 29.2, 36.2, 55.9, 56.4, 59.7, 68.2, 110.1, 112.5, 124.8, 127.6, 128.1, 146.9, 148.8, 157.5, 169.5; HRMS calcd for $C_{18}H_{21}BrNO_3Li~(M + H^+)$ 378.0705, found 378.0703.

7-Bromo-1-[2-(3,4-dimethoxyphenyl)ethyl]-1,4,5,6-tetrahydroindol-2-one (47). To a solution containing 0.6 g (1.9 mmol) of 44 in 20 mL of CH₂Cl₂ was added 0.38 g (2.1 mmol) of NBS. The reaction mixture was stirred for 1 h at 25 °C and was quenched by the addition of water. The mixture was extracted with CH₂Cl₂, and the combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. Purification of the residue by silica gel column chromatography provided 0.64 g (87%) of the brominated ene-amide 47 as tan solid: mp 122-124 °C; IR (neat) 2937, 1704, 1509, 1028 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.90 (quint, 2H, J = 6.4 Hz), 2.62 (dt, 2H, J = 6.4, 1.6 Hz), 2.81 (t, 2H, J = 6.4 Hz), 2.85 (ddd, 2H, J = 8.0, 5.6, 2.0 Hz),3.85 (s, 3H), 3.87 (s, 3H), 4.16 (ddd, 2H, J = 8.0, 5.6, 2.0 Hz),5.74 (s, 1H), 6.77–6.84 (m, 3H); 13 C NMR (CDCl₃, 100 MHz) δ 35.5, 37.7, 41.7, 55.73, 55.75, 107.6, 111.0, 112.0, 115.2, 120.7,131.0, 136.9, 147.4, 148.7, 148.8, 170.8; HRMS calcd for C₁₈H₂₀- $BrNO_3Li (M + Li^+) 384.0787$, found 384.0798.

7-Bromo-1-[2-(3,4-dimethoxyphenyl)ethyl]-7a-hydroxy-1,4,5,6,7,7a-hexahydroindol-2-one (48). To a solution containing 0.58 g (1.9 mmol) of **44** in 20 mL of THF was added 0.38 g (2.1 mmol) of NBS. The mixture was stirred for 1 h at 25 °C and was then quenched by the addition of water. The mixture was extracted with EtOAc, and the combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. Purification of the residue by silica gel column chromatography provided 0.59 g (77%) of aminal **48** as a white solid: mp 81–82 °C; IR (neat) 3251, 2946, 1681, 1514 cm^-1; ¹H NMR (CDCl₃, 400 MHz) δ 1.59 (brs, 1H), 1.76-1.92 (m, 2H), 1.98 (d, 1H, J = 13.6 Hz), 2.18-2.36 (m,2H), 2.59 (d, 1H, J = 13.6 Hz), 2.55-2.95 (m, 1H), 3.11 (ddd, 2H, J = 8.8, 6.0, 3.2 Hz), 3.85 (s, 3H), 3.86 (s, 3H), 3.83-3.87 (m, 1H), 4.50 (t, 1H, J = 2.8 Hz), 5.81 (d, 1H, J = 1.6 Hz), 6.74 (d, 1H, J = 1.6 Hz), 6.75 (dd, 1H, J = 8.0, 1.6 Hz), 6.81(d, 1H, J = 8.0 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 21.8, 25.2, 29.7, 34.2, 40.7, 54.7, 55.8, 89.7, 111.3, 112.1, 120.3, 120.6, 132.0, 147.5, 148.8, 158.3, 170.6; HRMS calcd for C₁₈H₂₂BrNO₄-Li (M + Li⁺) 402.0892, found 402.0910.

11,12-Dimethoxy-1,2,8,9-tetrahydroindolo[7a,1a]isoquinolin-6-one (49). To a solution containing 1.0 g (2.8 mmol) of 46 in 10 mL of xylene was added 3 mL of DBU at 25 °C. The reaction mixture was heated at reflux for 48 h with stirring. After cooling, water was added and the mixture was extracted with EtOAc. The combined organic layers were dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. Purification of the residue by silica gel column chromatography provided 0.62 g (75%) of the $\alpha, \beta, \gamma, \delta$ unsaturated diene-amide 49 as a clear oil: IR (neat) 2929, 1687, 1513 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.84 (dt, 1H, J = 12.0, 5.6 Hz), 2.14-2.26 (m, 1H), 2.32 (dd, 1H, J = 12.0, 4.6Hz), 2.41 (dt, 1H, J = 19.2, 5.6 Hz), 2.97 (t, 2H, J = 6.8 Hz), $3.55 \,(\text{dt}, 1\text{H}, J = 12.8, 6.8 \,\text{Hz}), 3.76 \,(\text{s}, 3\text{H}), 3.84 \,(\text{s}, 3\text{H}), 4.03$ (dt, 1H, J = 12.8, 6.8 Hz), 5.88 (s, 1H), 6.28 (ddd, 1H, J = 9.6,5.6, 2.0 Hz), 6.69 (s, 1H), 6.81 (dd, 1H, J = 9.6, 2.8 Hz), 7.00 (s, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ 24.5, 27.1, 34.9, 37.0, 55.8, 55.9, 64.6, 108.5, 112.0, 118.7, 123.9, 126.2, 128.5, 136.1, 146.8, 148.1, 158.0; HRMS calcd for $C_{18}H_{19}rNO_3Li$ (M + Li⁺) 304.1525, found 304.1516.

Formic Acid 11,12-Dimethoxy-6-oxo-2,6,8,9-tetrahydro-1H-indolo[7a,1a]isoquinolin-2-yl Ester (50). To a solution containing 0.55 g (1.8 mmol) of 49 in 7 mL of 1,4-dioxane at room temperature was added 2.0 g (18.5 mmol) of selenium dioxide and 0.85 g (18.5 mmol) of formic acid. The reaction mixture was heated at reflux for 7 days with stirring. After cooling, 15 mL of a 10% NaOH solution was added, and the mixture was extracted with CHCl₃. The combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. Purification of the residue by column chromatography provided 0.09 g (14%) of formate **50** as a yellow pale oil: IR (neat) 2933, 1720, 1686, 1512 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.87 (dd, 1H, J = 11.2, 10.4 Hz), 2.84 (dd, 1H, J = 11.2, 5.2 Hz), 2.93-3.103 (m, 2H), 3.58 (dt, 1H, J = 12.8, 6.4 Hz), 3.77 (s, 3H), 3.85 (s, 3H), 4.00 (dt, 1H, J = 12.8, 7.6 Hz), 5.44 - 5.52 (m, 1H), 6.08 (s, 1H), 6.17 (d, 1H, J = 10.0 Hz), 6.71 (s, 1H), 6.80 (s, 1H), 6.99 (dd, 1H, J = 10.0, 2.4 Hz), 8.02 (d, 1H, J = 1.2 Hz); ¹³C NMR (CDCl₃, 100 MHz) $\delta \ 27.0, \ 37.3, \ 41.1, \ 55.9, \ 56.1, \ 65.9, \ 68.1, \ 107.8, \ 112.4, \ 121.3,$ 125.6, 126.5, 127.8, 133.5, 147.2, 148.7, 155.9, 159.9, 170.6; HRMS calcd for C₁₉H₁₉NO₅ (M⁺) 341.1263, found 341.1263.

Another fraction isolated from the column contained 0.09 g (15%) of 2-hydroxy-11,12-dimethoxy-1,2,8,9-tetrahydroindolo-[7a,1a]isoquinolin-6-one (**51**) which was isolated as a tan solid: mp 230–232 °C; IR (KBR) 3419, 2927, 1680, 1510 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.70 (dd, 1H, J = 11.6, 10.0 Hz), 2.11 (brs, 1H), 2.81 (dd, 1H, J = 11.6, 4.8 Hz), 2.90–3.12 (m, 2H), 3.60 (ddd, 1H, J = 12.8, 6.8, 5.2 Hz), 3.75 (s, 3H), 3.85 (s, 3H), 3.91–4.02 (m, 1H), 4.30 (brs, 1H), 6.02 (s, 1H), 6.30 (d, 1H, J = 10.0, 2.4 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 27.0, 37.4, 45.0, 55.9, 56.1, 66.4, 66.6, 108.0, 112.2, 120.1, 123.5, 126.4, 128.4, 139.4, 147.0, 148.5, 157.3, 171.0; HRMS calcd for C₁₈H₁₉NO₄ (M⁺) 313.1314, found 313.1305.

Alcohol **51** could also be obtained from the solvolysis of formate **50**. To a solution of **50** (0.002 g, 0.064 mmol) in EtOH

(3 mL) was added 0.1 mL of acetyl chloride at 25 °C. The reaction mixture was stirred for 1 h at room temperature. Removal of the solvent under reduced pressure afforded 0.002 g (100%) of **51** as the exclusive product.

 (\pm) -Erysotramidine (2). To a mixture containing 0.09 g (0.27 mmol) of **51** in 7 mL of THF and 4 mL of methyl iodide was added 0.18 g (3.2 mmol) of NaOH and 0.17 g (0.8 mmol) of tetraethylammonium bromide. The reaction mixture was stirred for 36 h at room temperature. The solution was poured into ice-water, and the resulting mixture was extracted with CHCl₃. The combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. Purification of the residue by preparative TLC provided 0.08 g (91%) of (±)-erysotramidine 2 as a colorless oil:⁴² IR (neat) 2930, 1666, 1518 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.71 (dd, 1H, J = 11.6, 10.4 Hz), 2.80 (dd, 1H, J = 11.6, 4.4Hz), 2.90–3.24 (m, 2H), 3.34 (s, 3H), 3.61 (ddd, 1H, J = 12.8, 7.2, 6.0 Hz), 3.76 (s, 3H), 3.86 (s, 3H), 3.82-3.88 (m, 1H), 4.00 (ddd, 1H, J = 12.8, 8.4, 7.2 Hz), 6.02 (s, 1H), 6.33 (d, 1H, J = 12.8, 8.4, 7.2 Hz)10.0 Hz), 6.72 (s, 1H), 6.80 (s, 1H), 6.90 (dd, 1H, J = 10.0, 2.0Hz); $^{13}\mathrm{C}$ NMR (CDCl_3, 100 MHz) δ 27.0, 37.2, 41.3, 55.8, 56.0, 56.3, 66.3, 74.8, 108.1, 120.2, 124.1, 126.5, 128.6, 136.2, 146.9, 148.5, 157.0, 170.8; HRMS calcd for C₁₉H₂₁NO₄Li (M + Li⁺) 334.1631, found 334.1633.

Acknowledgment. We thank the National Institutes of Health (GM 59384) for generous support of this work. We also thank our colleague, Dr. Kenneth Hardcastle, for his assistance with the X-ray crystallographic studies together with Grant Nos.NSF CHE-9974864 and NIH S10-RR13673 and the University Research Committee of Emory University for funds to acquire a microwave reactor.

Supporting Information Available: Spectroscopic and experimental procedures for 7-bromo-1-(3,3-diethoxypropyl)-3a-methyl-1,3,3a,4,5,6-hexahydroindol-2-one and 1-(3,3-diethoxypropyl)-3a-methyl-7-vinyl-1,3,3a,4,5,6-hexahydroindol-2-one. ¹H and ¹³C NMR spectra for new compounds lacking elemental analyses together with an ORTEP drawing for structure **35**. The authors have deposited atomic coordinates for this structure with the Cambridge Crystallographic Data Centre. This material is available free of charge via the Internet at http://pubs.acs.org.

JO048647F

⁽⁴²⁾ Toda, J.; Niimura, Y.; Takeda, K.; Sano, T.; Tsuda, Y. Chem. Pharm. Bull. 1998, 46, 906.